Jefferies Financial Group Downgrades Atara Biotherapeutics (NASDAQ:ATRA) to Hold

Jefferies Financial Group downgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) from a buy rating to a hold rating in a research report report published on Monday morning, 24/7 WallStreet reports. The brokerage currently has $15.00 target price on the biotechnology company’s stock, down from their previous target price of $32.00. Jefferies Financial Group also issued estimates for Atara Biotherapeutics’ FY2021 earnings at ($4.78) EPS, FY2022 earnings at ($4.33) EPS and FY2023 earnings at ($2.92) EPS.

Several other research analysts have also issued reports on ATRA. BidaskClub raised Atara Biotherapeutics from a sell rating to a hold rating in a research report on Tuesday, September 10th. Mizuho set a $43.00 target price on Atara Biotherapeutics and gave the stock a buy rating in a research report on Wednesday, September 11th. Roth Capital started coverage on Atara Biotherapeutics in a research note on Friday, September 13th. They issued a buy rating and a $30.00 price target on the stock. Cowen restated a buy rating on shares of Atara Biotherapeutics in a research note on Friday, September 13th. Finally, Wedbush restated an outperform rating on shares of Atara Biotherapeutics in a research note on Wednesday, May 29th. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Atara Biotherapeutics has an average rating of Buy and an average price target of $32.71.

Shares of NASDAQ:ATRA opened at $15.23 on Monday. Atara Biotherapeutics has a 52-week low of $11.89 and a 52-week high of $43.95. The firm has a market capitalization of $805.83 million, a P/E ratio of -2.89 and a beta of 2.10. The stock has a 50 day moving average price of $13.80 and a 200-day moving average price of $24.29. The company has a debt-to-equity ratio of 0.06, a quick ratio of 7.80 and a current ratio of 7.80.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.45) by ($0.15). On average, equities analysts forecast that Atara Biotherapeutics will post -5.71 EPS for the current fiscal year.

In related news, Director Eric Dobmeier purchased 2,000 shares of the business’s stock in a transaction that occurred on Thursday, June 27th. The shares were bought at an average price of $19.50 per share, for a total transaction of $39,000.00. Following the purchase, the director now directly owns 16,000 shares of the company’s stock, valued at approximately $312,000. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 7.00% of the company’s stock.

Several institutional investors have recently bought and sold shares of the stock. Manchester Capital Management LLC purchased a new stake in Atara Biotherapeutics during the 1st quarter valued at $56,000. Aperio Group LLC purchased a new stake in Atara Biotherapeutics during the 2nd quarter valued at $63,000. Marshall Wace LLP purchased a new stake in Atara Biotherapeutics during the 1st quarter valued at $284,000. Xact Kapitalforvaltning AB boosted its stake in Atara Biotherapeutics by 37.3% during the 1st quarter. Xact Kapitalforvaltning AB now owns 8,100 shares of the biotechnology company’s stock valued at $322,000 after purchasing an additional 2,200 shares during the last quarter. Finally, Bank of Montreal Can boosted its stake in Atara Biotherapeutics by 81.1% during the 2nd quarter. Bank of Montreal Can now owns 8,314 shares of the biotechnology company’s stock valued at $167,000 after purchasing an additional 3,723 shares during the last quarter. Institutional investors own 91.79% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

See Also: Hedge Funds – Risk or Reward?

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit